compounding, weight loss and food and drug administration

Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Compound versions of some weight loss drugs to be restricted
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for weight loss, as is permissible by the FDA.
Ending of US weight-loss drug shortages prompts compounder complaints
Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US, according to the US Food and Drug Administration (FDA). That means that compounding pharmacies and outsourcing facilities that had been legitimately preparing their own versions of the drugs will no longer be permitted to do so.
How weight-loss drugs could help treat addiction, arthritis, more
Popular weight-loss drugs like Ozempic and Wegovy are known for helping people who are looking to shed some pounds, but research suggests they could offer other life-changing benefits. Dr. Natalie Azar joins TODAY to talk about some of the clinical trials and the potential benefits on issues including sleep apnea,
The State of Weight Loss Drugs
How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about Ozempic's and Mounjarno's patent cliffs. The scenarios in which Novo Nordisk and Eli Lilly are actually undervalued.
Who can get weight loss drugs on the NHS in Scotland?
The medicines watchdog has agreed the drugs are safe and cost-effective for NHS use. Last year, semaglutide was approved for treating obesity under the brand name Wegovy. It has also been licensed under the brand name Ozempic for treating diabetes in some circumstances,
Compound versions of weight loss drugs will no longer be available, FDA rules
Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available after a decision by the U.S. Food and Drug Administration. The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply.
Medications For Weight Loss
Dr. Alexandro Zarruk, MD, MSc., FACP, FRCPC, Internal Medicine, talks about medications that can help patients lose weight.
Patients, doctors voice frustration over restricted access to weight loss drugs
A federal judge’s ruling restricts compounding pharmacies from producing generic Zepbound, sparking concerns over affordability
Ozempic vs Metformin For Weight Loss: Which Is Best for Me?
The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...
Popular weight loss drugs bring unexpected heart health benefits—researchers discuss implications
Weight loss drugs like Ozempic deliver more health benefits than expected. In a study published in the journal Life, ...
New Discovery Promises Weight Loss Without Ozempic's Side Effects
Stanford Medicine researchers have identified a naturally occurring molecule that mimics the appetite-suppressing effects of ...
Morningstar2d
Ozempic parent's new weight-loss drug works better, but not quite good enough
CagriSema, which is a combination of cagrilintide 2.4-milligram and semaglutide 2.4-mg doses, is being developed so people have a better choice for a weight-loss drug when the patents on ...
Weight loss drugs at home: the controversial idea from the creator of Ozempic that is triumphing in the United States
Danish pharmaceutical company Novo Nordisk turned the market upside down when it launched Ozempic, a diabetes drug that ended ...
New York Post4d
We went blind after using weight-loss drugs like Ozempic and Mounjaro
Recent studies have shown an association between drugs such as Ozempic, Mounjaro and Wegovy — which have become phenomenally popular for weight loss — and an increased risk of NAION.
The Financial Express1d
Popular weight loss drugs Ozempic and Mounjaro hold potential to transform type 1 diabetes treatment: GlobalData
Despite the promising results, further research is needed before GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists ...